Laura Muñoz-Barrera, Carlos Perez-Sanchez, Rafaela Ortega-Castro, Sagrario Corrales, Maria Luque-Tevar, Tomás Cerdó, Ismael Sanchez-Pareja, Pilar Font, Raquel Lopez-Mejías, Jerusalem Calvo, M Carmen Abalos-Aguilera, Desiree Ruiz-Vilchez, Pedro Segui, Christian Merlo, José Perez-Venegas, Ma Dolores Ruiz Montesino, Carlos Rodriguez-Escalera, Carmen Romero Barco, Antonio Fernandez-Nebro, Natalia Mena Vazque, Jose Luis Marenco, Julia Uceda Montañes, Javier Godoy-Navarrete, Alba Ma Cabezas-Lucena, Eduardo Collantes Estevez, Ma Angeles Aguirre, Miguel A González-Gay, Nuria Barbarroja, Alejandro Escudero-Contreras, Chary Lopez-Pedrera
BACKGROUND & OBJECTIVES: This study aimed to: 1) analyze the inflammatory profile of Rheumatoid Arthritis (RA) patients, identifying clinical phenotypes associated with cardiovascular (CV) risk; 2) evaluate biologic and targeted-synthetic disease-modifying antirheumatic drugs (b-DMARDs and ts-DMARDs': TNFi, IL6Ri, JAKinibs) effects; and 3) characterize molecular mechanisms in immune-cell activation and endothelial dysfunction. PATIENTS & METHODS: A total of 387 RA patients and 45 healthy donors were recruited, forming three cohorts: i) 208 RA patients with established disease but without previous CV events; ii) RA-CVD: 96 RA patients with CV events, and iii) 83 RA patients treated with b-DMARDs/ts-DMARDs for 6 months...
April 2024: Biomedicine & Pharmacotherapy